Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

686 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase II study of clinical outcomes of 3-week cycles of irinotecan and S-1 in patients with previously untreated metastatic colorectal cancer: influence of the UGT1A1 and CYP2A6 polymorphisms on clinical activity.
Choi YH, Kim TW, Kim KP, Lee SS, Hong YS, Ryu MH, Lee JL, Chang HM, Ryoo BY, Kim HS, Shin JG, Kang YK. Choi YH, et al. Among authors: kim tw, kim kp, kim hs. Oncology. 2012;82(5):290-7. doi: 10.1159/000337989. Epub 2012 Apr 28. Oncology. 2012. PMID: 22555197 Clinical Trial.
Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy.
Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH, Lee KW, Kim TY, Kim TW. Hong YS, et al. Among authors: kim tw, kim kp, kim ty, kim sy, kim jh. Invest New Drugs. 2013 Feb;31(1):183-91. doi: 10.1007/s10637-012-9853-3. Epub 2012 Jul 11. Invest New Drugs. 2013. PMID: 22782485 Clinical Trial.
Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group CO06-01.
Hong YS, Jung KH, Kim HJ, Kim KP, Kim SY, Lee JL, Shim BY, Zang DY, Kim JH, Ahn JB, Park YS, Kim TW. Hong YS, et al. Among authors: kim hj, kim tw, kim kp, kim sy, kim jh. Am J Clin Oncol. 2013 Dec;36(6):565-71. doi: 10.1097/COC.0b013e31825d52d5. Am J Clin Oncol. 2013. PMID: 22868243 Clinical Trial.
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW, Chung IJ, Cho SH, Lee KH, Shin SJ, Kang HJ, Shin DB, Jo SJ, Lee JW. Hong YS, et al. Among authors: kim tw, kim kp, kim sy, kim jh. Lancet Oncol. 2012 Nov;13(11):1125-32. doi: 10.1016/S1470-2045(12)70363-7. Epub 2012 Oct 10. Lancet Oncol. 2012. PMID: 23062232 Clinical Trial.
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
Hong YS, Lee SS, Kim KP, Lee JL, Kang YK, Shin SJ, Ahn JB, Jung KH, Im SA, Kim TY, Kim JH, Park YS, Kim TW. Hong YS, et al. Among authors: kim tw, kim kp, kim ty, kim jh. Am J Clin Oncol. 2014 Feb;37(1):19-23. doi: 10.1097/COC.0b013e31826b9c94. Am J Clin Oncol. 2014. PMID: 23111359 Clinical Trial.
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Hong YS, et al. Among authors: kim tw, kim kp, kim ty, kim sy, kim jc, kim je, kim jh. Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4. Lancet Oncol. 2014. PMID: 25201358 Clinical Trial.
Postoperative radiotherapy for gallbladder cancer.
Jeong Y, Park JH, Lee YJ, Park KM, Hwang S, Chang HM, Kim KP, Yoon SM, Jung NH, Kim JH. Jeong Y, et al. Among authors: kim kp, kim jh. Anticancer Res. 2014 Oct;34(10):5621-9. Anticancer Res. 2014. PMID: 25275065
686 results